Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with rio...

Disgrifiad llawn

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Prif Awduron:	Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias Lange, Karen M. Olsson, Hans Klose, Ekkehard Grünig
Fformat:	Artigo
Iaith:	Saesneg
Cyhoeddwyd:	2018
Mynediad Ar-lein:	https://doi.org/10.1186/s12931-018-0957-y https://respiratory-research.biomedcentral.com/track/pdf/10.1186/s12931-018-0957-y
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
gan: Marra, Alberto M., et al.
Cyhoeddwyd: (2018)

Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
gan: Alberto M. Marra, et al.
Cyhoeddwyd: (2015)

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
gan: Christina A. Eichstaedt, et al.
Cyhoeddwyd: (2022)

Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
gan: Hossein Ardeschir Ghofrani, et al.
Cyhoeddwyd: (2010)

Practical management of riociguat in patients with pulmonary arterial hypertension
gan: Halank, Michael, et al.
Cyhoeddwyd: (2019)

Riociguat for the Treatment of Pulmonary Arterial Hypertension
gan: Hossein Ardeschir Ghofrani, et al.
Cyhoeddwyd: (2013)

Pulmonary Hypertension
gan: M. Hoeper, Marius, et al.
Cyhoeddwyd: (2017)

Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up
gan: Xanthouli, Panagiota, et al.
Cyhoeddwyd: (2020)

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
gan: Eichstaedt, Christina A., et al.
Cyhoeddwyd: (2022)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
gan: Ghofrani, Hossein A, et al.
Cyhoeddwyd: (2009)

EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension
gan: Eichstaedt, Christina A., et al.
Cyhoeddwyd: (2016)

EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension
gan: Christina A. Eichstaedt, et al.
Cyhoeddwyd: (2016)

Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension—A Genetic Study
gan: Eichstaedt, Christina A., et al.
Cyhoeddwyd: (2020)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
gan: Kim, Nick H, et al.
Cyhoeddwyd: (2017)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
gan: Nick H. Kim, et al.
Cyhoeddwyd: (2016)

Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease
gan: Ghofrani, Hossein A., et al.
Cyhoeddwyd: (2015)

Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a cross-sectional study
gan: Fischer, Lukas, et al.
Cyhoeddwyd: (2018)

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
gan: Hossein Ardeschir Ghofrani, et al.
Cyhoeddwyd: (2013)

Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension
gan: Xanthouli, Panagiota, et al.
Cyhoeddwyd: (2021)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
gan: Ghofrani, Hossein-Ardeschir, et al.
Cyhoeddwyd: (2020)

Effects of riociguat in severe experimental pulmonary hypertension
gan: Kojonazarov, Baktybek, et al.
Cyhoeddwyd: (2011)

Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension
gan: Hossein Ardeschir Ghofrani, et al.
Cyhoeddwyd: (2016)

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)
gan: Pan, Zixuan, et al.
Cyhoeddwyd: (2019)

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)
gan: Zixuan Pan, et al.
Cyhoeddwyd: (2019)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
gan: Hoeper, Marius M., et al.
Cyhoeddwyd: (2017)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
gan: Marius M. Hoeper, et al.
Cyhoeddwyd: (2017)

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
gan: Lewis J. Rubin, et al.
Cyhoeddwyd: (2015)

Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial
gan: Marius M. Hoeper, et al.
Cyhoeddwyd: (2012)

Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis
gan: Gerry Coghlan, et al.
Cyhoeddwyd: (2018)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
gan: Harzheim, Dominik, et al.
Cyhoeddwyd: (2013)

General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018
gan: Ekkehard Grünig, et al.
Cyhoeddwyd: (2018)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
gan: Dominik Harzheim, et al.
Cyhoeddwyd: (2013)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
gan: Stephan Rosenkranz, et al.
Cyhoeddwyd: (2015)

Switching to Riociguat from Phosphodiesterase-5 Inhibitors, With or Without Endothelin Receptor Antagonists, in Patients with Pulmonary Arterial Hypertension: Results from the REPLACE Study
gan: G. Meyer, et al.
Cyhoeddwyd: (2021)

Pulmonary arterial hypertension-related myopathy: An overview of current data and future perspectives
gan: Alberto M. Marra, et al.
Cyhoeddwyd: (2014)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
gan: McLaughlin, Vallerie V., et al.
Cyhoeddwyd: (2017)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
gan: Vallerie V. McLaughlin, et al.
Cyhoeddwyd: (2017)

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?
gan: Theobald, Vivienne, et al.
Cyhoeddwyd: (2022)

Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction
gan: Diana Bonderman, et al.
Cyhoeddwyd: (2013)

Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
gan: Marius M. Hoeper, et al.
Cyhoeddwyd: (2017)